U.S. Markets closed

Supernus Pharmaceuticals, Inc. (SUPN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
33.19+1.27 (+3.98%)
At close: 4:00PM EDT
33.19 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close31.92
Open32.00
Bid33.21 x 800
Ask33.26 x 800
Day's Range32.00 - 34.29
52 Week Range17.20 - 34.29
Volume861,297
Avg. Volume500,290
Market Cap1.76B
Beta (5Y Monthly)1.20
PE Ratio (TTM)14.06
EPS (TTM)2.36
Earnings DateAug 16, 2021 - Aug 20, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.00
  • Supernus Pharmaceuticals Stock Getting Closer To Key Technical Measure
    Investor's Business Daily

    Supernus Pharmaceuticals Stock Getting Closer To Key Technical Measure

    A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance. Will it continue?

  • Supernus Pharmaceuticals (NASDAQ:SUPN) Could Easily Take On More Debt
    Simply Wall St.

    Supernus Pharmaceuticals (NASDAQ:SUPN) Could Easily Take On More Debt

    Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

  • Supernus to Present at Jefferies Virtual Healthcare Conference
    GlobeNewswire

    Supernus to Present at Jefferies Virtual Healthcare Conference

    ROCKVILLE, Md., May 25, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021, at 1:30 p.m. ET. A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com. An archived replay will be available for 60 days on the Company's website following the conference. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson’s disease, epilepsy, depression, and rare CNS disorders. For more information, please visit www.supernus.com. CONTACTS: Jack A. Khattar, President and CEOJim Kelly, Executive Vice President and CFOSupernus Pharmaceuticals, Inc.Tel: (301) 838-2591 Or Investor Contact:Peter VozzoWestwicke/ICROffice: (443) 213-0505Mobile: (443) 377-4767Email: peter.vozzo@westwicke.com